MELBOURNE, Fla., Jan. 14, 2022 /PRNewswire/ -- Sun Nuclear
Corporation (Sun Nuclear), a wholly-owned subsidiary of Mirion
Technologies, Inc. (NYSE: MIR) ("Mirion"), today announced the full
program for the 2022 QA & Dosimetry Symposium (QADS),
April 8-9, in Orlando, Florida. Hosted by Sun Nuclear, QADS
is the premier Continuing Education event focused exclusively on
Quality and Patient Safety in Radiation Oncology. In its
13th occurrence, QADS offers attendees timely and
clinically relevant continuing education.
2 Days, 6 Session Themes, 20+ Presentations
QADS
attendees can expect lively discussion and continuing education on
diverse topics across six session themes:
- Safety & Quality Control in Challenging Environment
- Cybersecurity in Healthcare
- Commissioning & QA for Stereotactic Modalities
- Advances in Treatment Delivery & Quality Assurance
- How to Detect Errors in Patient Treatment
- Practical Dosimetry & QA
"With QADS, our aim is to present topics that are most relevant
to the medical physics community right now, building a program
based on insights from industry associations, publications,
community discussion forums, and feedback from our global customer
base," said Eric Schloesser, Sun
Nuclear President. "We're pleased to share the 2022 program,
featuring multidisciplinary talks with practical guidance on
Quality Assurance."
Many cancer centers and radiation therapy departments cite
cyberattacks and the COVID-19 pandemic as major disruptors for
them, leading to workflow interferences and operational
discontinuity. QADS will feature a session on these particular
challenges, including keynote presentation Cybersecurity Issues
in RT and Solutions, as well as a presentation on Incident
Learning in Challenging Times - A Physician's Perspective,
addressing the pandemic through the lens of incident learning and
how clinical processes have changed for the short-term or
beyond.
Sun Nuclear is also pleased to welcome Ehsan Samei, Ph.D., to its QADS program. Dr.
Samei is the Chief Imaging Physicist at Duke
University, the AAPM President Elect, and the founder of the
AAPM Medical Physics 3.0 initiative, with the goal to redefine,
reinvigorate, and promote the practice of sustainable excellence in
medical physics. He will present learnings from this initiative and
the implications for Diagnostic Imaging Quality Assurance.
The full QADS program can be seen at qasymposium.com. QADS has
applied to CAMPEP for approval of 14 MPCEC hours. QADS is also
seeking MDCB, SAM credits, as well as Medical Error and
General Credits approved by the FL Council of Medical
Physicists.
Registration to attend QADS is open now, and early registration
pricing is available through January 21,
2022. QADS will take place at the JW Marriot Orlando, Bonnet
Creek Resort and Spa. Sun Nuclear is committed to following all
COVID-related protocols in accordance with the World Health
Organization and the U.S. Centers for Disease Control for the
safety of all attendees, speakers and staff in attendance.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934. Words such as "anticipate,"
"believe," "continue," "could," "estimate," "expect," "hope,"
"intend," "may," "might," "should," "would," "will," "understand"
and similar words are intended to identify forward looking
statements. These forward-looking statements include but are not
limited to, statements regarding the technology and benefits of the
Mirion product's technology for Mirion and its customers. There are
a significant number of factors that could cause actual results to
differ materially from statements made in this press release,
including those described under the captions "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" set forth from time to time in filings and
reports we make from time to time with the Securities and Exchange
Commission, including our most recent Quarterly Report on Form
10-Q.
You should not rely on these forward-looking statements, as
actual outcomes and results may differ materially from those
contemplated by these forward-looking statements as a result of
such risks and uncertainties. All forward-looking statements in
this press release are based on information available to us as of
the date hereof, and we do not assume any obligation to update the
forward-looking statements provided to reflect events that occur or
circumstances that exist after the date on which they were
made.
About Sun Nuclear Corporation
Sun Nuclear, a
wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR)
provides innovative solutions for Radiation Therapy and Diagnostic
Imaging centers. Our mission is to enable healthier lives by
improving the avoidance, detection and treatment of cancer. More
than 5,000 cancer centers worldwide rely on us for independent,
integrated Quality Management. With a focus on ongoing support, we
aim to ease technology adoption, enhance workflows and improve
outcomes – so that healthcare providers can achieve real results
for Patient Safety. Visit us: sunnuclear.com. Follow us:
@sunnuclear.
Contacts
For investor
inquiries:
Brian Schopfer
ir@mirion.com
For media inquiries:
Matthew
Maddox
mmaddox@mirion.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sun-nuclear-announces-2022-qa--dosimetry-symposium-qads-program-301461296.html
SOURCE Sun Nuclear Corporation